Table 3 Dasatinib treatment and response... | American Society of Hematology

Table 3

Dasatinib treatment and response in evaluable patients

Patient no.	Dasatinib dose	Dose regimen	Dasatinib treatment duration, mo	Concurrent intrathecal therapy	Best response	Response duration, mo	Therapy details
1	140 mg/day, reduced due to toxicity to 50 mg × 5 days/week at 8 months	BID	13	No	CR	11	DXM at the beginning
2	140 mg/day	BID	5+	Yes	CR	5+	IT therapy prior to start of dasatinib with poor results, received three IT therapies* after dasatinib start
3	60 mg/m² (25 days) then 80 mg/m² per day	QD	10+	No	CR	6	IT therapy initiated at 6 months for relapse
4	60 mg/m² (29 days) then 80 mg/m² per day	QD	4	No	CR	3	IT therapy initiated at 3 months due to systemic relapse
5	140 mg/day	BID	3+	No	Radiologic CR	3+	None
6	140 mg/day	QD	22+	No	Clinical CR	22+	DXM at the beginning
7	140 mg/day then 200 mg/day at 4 months	BID	21	No	PR	6	IT therapy and later cranial radiation when treatment was intensified after 6 months due to relapse
8	140 mg/day for 3 months, varying dosing with long interruptions, currently 50 mg every other day	QD	26+	Yes	PR	26+	DXM, IT therapy*†‡
9	140 mg/day	BID	3+	Yes	VGPR	3+	IT therapy*†
10	60 mg/m² per day	QD	1.8	Yes	CR	1.5	Systemic steroids, IT therapy*†‡
11	80 (39 days), 120 (20 days) then 160 mg/m² per day	BID	2	Yes	CR	2	IT therapy*

Patient no.	Dasatinib dose	Dose regimen	Dasatinib treatment duration, mo	Concurrent intrathecal therapy	Best response	Response duration, mo	Therapy details
1	140 mg/day, reduced due to toxicity to 50 mg × 5 days/week at 8 months	BID	13	No	CR	11	DXM at the beginning
2	140 mg/day	BID	5+	Yes	CR	5+	IT therapy prior to start of dasatinib with poor results, received three IT therapies* after dasatinib start
3	60 mg/m² (25 days) then 80 mg/m² per day	QD	10+	No	CR	6	IT therapy initiated at 6 months for relapse
4	60 mg/m² (29 days) then 80 mg/m² per day	QD	4	No	CR	3	IT therapy initiated at 3 months due to systemic relapse
5	140 mg/day	BID	3+	No	Radiologic CR	3+	None
6	140 mg/day	QD	22+	No	Clinical CR	22+	DXM at the beginning
7	140 mg/day then 200 mg/day at 4 months	BID	21	No	PR	6	IT therapy and later cranial radiation when treatment was intensified after 6 months due to relapse
8	140 mg/day for 3 months, varying dosing with long interruptions, currently 50 mg every other day	QD	26+	Yes	PR	26+	DXM, IT therapy*†‡
9	140 mg/day	BID	3+	Yes	VGPR	3+	IT therapy*†
10	60 mg/m² per day	QD	1.8	Yes	CR	1.5	Systemic steroids, IT therapy*†‡
11	80 (39 days), 120 (20 days) then 160 mg/m² per day	BID	2	Yes	CR	2	IT therapy*

BID indicates twice daily; QD, once daily; CR, complete response; PR, partial response; VGPR, very good partial response; DXM, dexamethasone; and IT therapy, intrathecal therapy.

Cytarabine.

†

Methotrexate.

‡

Prednisolone.

View Large

This Feature Is Available To Subscribers Only